NEW YORK, Nov. 07, 2019 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that its ...

First three patients underwent successful implantation and clinical utilization of PortIO as part of a first-in-human study in Colombia, South America NEW YORK--(BUSINESS WIRE)--PAVmed Inc. (Nasdaq: ...

March 11, 2008 — The US Food and Drug Administration (FDA) has granted 510(k) clearance for a handheld device for the measurement of airway inflammation, an intraosseous infusion system for use in ...

Potential Savings of $95 Million Annually if Only Ten Percent of Central Lines Are Replaced with IO Access Success rate of 96% in establishing vascular access on first attempt; Mean time to vascular ...

* Pavmed Inc - co has decided to follow fda s encouragement and pursue a de novo classification for portio under a broader indication, for up to 7 days * Pavmed - ‍ after pursuing de novo ...

Pavmed Inc. implanted its Portio system in three patients in a first-in-human (FIH) study of its intraosseous infusion system and successfully infused fluids in all patients without complications. The ...

VANCOUVER, BRITISH COLUMBIA--(Marketwire - Jan. 10, 2012) - Pyng Medical Corp. (the "Company") (TSX VENTURE:PYT.V - News) announced today that the FAST1(R) has been chosen by the Spanish Army through ...

The following text summarizes information provided in the video. The medullary cavity is a highly vascular structure that functions as a noncollapsible vein capable of accepting a large volume of ...

NEW YORK--(BUSINESS WIRE)--PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a diversified commercial-stage medical technology company, today announced that physicians at the Clinica ...

FDA pre-submission meeting date supporting de novo application secured Broad method and device patents granted by USPTO NEW YORK, Nov. 07, 2019 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ...